Cancer senescence: licence to killTherapy-induced senescence (TIS), a lasting chemotherapy-evoked proliferative arrest of tumor cells, has been thought to be irreversible. As it turns out now, it makes tumour cells, which survive, more … more ➔
Sheets of eye cells improve retina repairScientists have generated sheets of human eye cells arranged on a biological scaffold, which they used to successfully treat vision disorders in rats. more ➔
Roche does not have to pay US$685m fineThe European Commission has closed its very first infringement procedure under the Penalty Regulation. During an inspection at Roche’s UK headquarters in 2012 the British MHRA found data on 80,000 not … more ➔
A new fund from the northHadean Ventures announced the launch of Hadean Capital I, a fund that will invest up to € 100 m in life science companies, with a particular focus on the Nordic region. more ➔
CHMP recommends EU approval of seven medic...The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval at its December 2017 meeting, including two orphan medicines, and one b … more ➔
reMYND in €350m diabetes deal with Novo Belgian reMYND N.V. has out licenced worldwide commercialisation rights for its small molecule programme ReS39 in diabetes to Novo Nordisk A/S. The drug impedes death of insulin-producing beta cells … more ➔
TB urine test outperforms standard of careA new, non-invasive tuberculosis urine test prevents common disadvantages of the standard tuberculin skin test: Measuring lipoarabinomannan glycan from M. tuberculosis, it detects the active disease … more ➔
LSP raises €280m for late-stage med-tech...Life sciences investment group LSP has launched the largest fund in Europe dedicated to late-stage medical technology assets, including diagnostics and digital health. more ➔
Aelin Therapeutics NV bags €27m in Serie...Belgian start-up company Aelin Therapeutics NV secured the funds to push development of candidate drugs arising from its Pept-in protein knockdown platform, which harnesses protein aggregation to induce … more ➔
ArgenX reports hints to efficacy of ARGX-1...Dutch llama antibody specialist ArgenX met the safety endpoint in a Phase II trial with ARGX 113 (efgartigimod), a first-in-class antibody that lowers pathogenic levels of IgG, in patients with the autoimmune … more ➔
